SURPASS-CVOT and Tirzepatide, a Dual GIP/GLP-1 RA, in ASCVD

In this episode of Don’t Miss a Beat, hosts Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, sit down with Darren McGuire, MD, to explore the groundbreaking results of the SURPASS-CVOT trial. This cardiovascular outcome study is the first to directly compare two incretin-based therapies—tirzepatide, a dual GIP/GLP-1 receptor agonist, and dulaglutide, a GLP-1 receptor agonist—among patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD). Unlike the placebo-controlled GLP-1 programs of the past decade, SURPASS-CVOT represents a pivotal move toward active comparator trials in cardiometabolic medicine. 00:00:00 Intro 00:01:35 Behind the trial 00:04:35 What is imputed placebo? 00:08:32 The size and scope of SURPASS-CVOT 00:11:01 Results of SURPASS-CVOT 00:14:20 How to select comparators among obesity medicines 00:17:37 Future trials 00:18:56 Interpreting these new kinds of comparisons 00:20:50 Active comparators are the future 00:24:01 Closing

There are no comments yet.

Please log in to write the first comment.